PrEP: latest news

PrEP resources

  • How to get PrEP in the UK

    In England, PrEP is available to people taking part in the PrEP Impact trial.In Wales and Scotland, PrEP is available through NHS sexual health clinics.It is also...

    From: Factsheets

    Information level Level 2
  • Pre-exposure prophylaxis (PrEP)

    PrEP is highly effective in preventing the sexual transmission of HIV. For PrEP to work well, it’s important to take the pills regularly.While PrEP can...

    From: Factsheets

    Information level Level 2
  • Using anti-HIV drugs to prevent HIV

    The goal of HIV treatment is an undetectable viral load. An undetectable viral load means that your blood has a level of HIV below the level which...

    From: Booklets

    Information level Level 2
  • PrEP

    This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing...

    From: HIV prevention briefing papers

  • Pre-exposure prophylaxis

    Pre-exposure prophylaxis is an experimental HIV-prevention strategy that would use antiretrovirals (ARVs) to protect HIV-negative people from HIV infection....

    From: Preventing HIV

    Information level Level 4

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • PrEP campaigns must include youth, communities of color

    Sandy Close, moderating a panel on how to close the information gap on PrEP in underserved communities, called it a “break the silence issue,” referring to the stigma and misconceptions about PrEP and HIV. Misinformation about the drug is all too rampant. Too many from communities of color believe the drug is not for them.

    19 November 2017 | San Francisco Examiner
  • New Zealand AIDS Foundation welcomes PHARMAC’s milestone proposal to fund Pre-exposure Prophylaxis (PrEP)

    In a proposal released today, PHARMAC has announced its intention to fund the HIV-prevention drug PrEP – meaning the medicine is one step closer to becoming available to those at highest risk of HIV in New Zealand.

    14 November 2017 | New Zealand AIDS Foundation
  • British Columbia just lost its last two excuses not to cover the pill that prevents HIV

    Julio Montaner, the head of the BC Centre for Excellence in HIV/AIDS, told a room full of doctors and activists Nov 6, 2017, that his centre has negotiated a deal with generic drug manufacturers that could deliver the treatment without swelling the budget. “The message is, we’re ready,” Montaner told Xtra following his announcement. “It’s time to do this.”

    13 November 2017 | XTRA, Vancouver
  • Danish court invalidates Gilead SPC

    The Danish Maritime and Commercial High Court has invalidated a supplementary protection certificate (SPC) owned by Gilead. On October 26, the court rejected Gilead’s motion for an injunction against generics maker Accord.

    10 November 2017 | Life Sciences Intellectual Property Review
  • Ireland’s first clinic monitoring anti-HIV drug PrEP opens

    The clinic will be open to users of the drug and will provide HIV tests and STI screening; it will not supply the drug.

    10 November 2017 | The Irish Times
  • Gilead loss of generic HIV drug battle a boost for gay community

    09 November 2017 | The Irish Times
  • The future of PrEP in Australia

    PrEP has been a major discussion point in the 2017 ASHM conference. In a joint symposium with the 2017 Sexual Health Conference, multiple speakers spoke of the rollout of PrEP in Australia and New Zealand.

    08 November 2017 | Australian Society for HIV Medicine Report Back
  • PrEP and reaching people of color, trans women, and young people

    Not everyone at risk for HIV knows about PrEP, and many people who could benefit from PrEP believe it’s not for them. A recent panel discussion in San Francisco explored this issue. Speaking about their work and the diverse communities they serve, the panelists shared some of the important barriers that people of color, trans women and young people face related to PrEP knowledge, access and adherence.

    08 November 2017 | BETA blog
  • I’m one of the people in England trialling a new drug that virtually stops the spread of HIV

    There’s a quiet revolution going on in sexual health at the moment. I’m one of thousands of people are taking a pill every day to stop unwanted consequences of sex.

    07 November 2017 | The Overtake
  • Uptake of medications for HIV treatment and prevention changes sexual practices

    The Annual Report of Trends in Behaviour 2017 released today by the Centre for Social Research in Health (CSRH) at UNSW Sydney finds the proportion of non-HIV-positive gay men who reported pre-exposure prophylaxis (PrEP) use in the six months prior to the annual Gay Community Periodic Surveys increased from 2% in 2013 to 5% in 2016.

    06 November 2017 | University of New South Wales
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.